# TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.

> **NCT00245739** · — · APPROVED_FOR_MARKETING · sponsor: **Tibotec Pharmaceuticals, Ireland**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** TMC-114

## Key facts

- **NCT ID:** NCT00245739
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2014-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00245739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00245739, "TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT00245739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*